Transient Abnormal Myelopoiesis Associated with Down Syndrome
NCI Definition: A myeloid proliferation occurring in newborns with Down syndrome. It is clinically and morphologically indistinguishable from acute myeloid leukemia and is associated with GATA1 mutations. The blasts display morphologic and immunophenotypic features of megakaryocytic lineage. In the majority of patients the myeloid proliferation undergoes spontaneous remission. 
There is 1 clinical trial for transient abnormal myelopoiesis associated with down syndrome, of which 1 is open and 0 are completed or closed. Of the trial that contains transient abnormal myelopoiesis associated with down syndrome as an inclusion criterion, 1 is phase 3 (1 open).
Cytarabine, daunorubicin, and etoposide are the most common interventions in transient abnormal myelopoiesis associated with down syndrome clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.